Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule for nasal irrigation or nebulizer use containing acetylcysteine sodium, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing acetylcysteine are listed in solution, injection and inhalant forms. No acetylcysteine product of any kind is listed in capsule form. None of the FDA-approved acetylcysteine products is for nasal use.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Acetylcysteine (NAC) is a mucus-thinning and antioxidant medicine that compounding pharmacies prepare as oral capsules, inhalation solutions and ophthalmic drops.
Acetylcysteine is the N-acetyl form of the amino acid cysteine. Its sulfhydryl group opens the disulfide bonds that hold mucus together, lowering its viscosity, and in the body it supplies cysteine so the liver can rebuild glutathione, its main detoxifying antioxidant. Two kinds of manufactured product exist. Acetadote (Cumberland Pharmaceuticals) is an injection FDA-approved to prevent or lessen liver injury after a potentially toxic acetaminophen ingestion. Acetylcysteine solution for inhalation (for example American Regent) is FDA-approved as adjuvant therapy for abnormal, viscid or inspissated mucus in bronchopulmonary disease, cystic fibrosis and tracheostomy care, and orally for acetaminophen overdose. No FDA-approved acetylcysteine capsule or eye drop is marketed; an FDA-approved effervescent tablet for acetaminophen overdose (Cetylev) was approved in 2016 and is listed by FDA as discontinued. Prescribers may order it compounded as capsules in a chosen strength, as ophthalmic drops, or in a vehicle free of a given excipient. Compounded preparations are not FDA-approved and require a prescription.
Neither manufactured label carries a boxed warning. Acetylcysteine is contraindicated in anyone who has had a hypersensitivity reaction to it; the Acetadote label warns of serious acute reactions including anaphylaxis, rash and low blood pressure. Inhaled acetylcysteine can trigger chest tightness and bronchospasm, so people with asthma should be watched closely, and it liquefies secretions that may need suctioning. Other reported effects include mouth irritation, nausea, vomiting, runny nose, fever, drowsiness and a disagreeable odor that fades. Reviews note low blood pressure and headache with nitroglycerin and lowered carbamazepine levels. The inhalation label says to use it in pregnancy only if clearly needed, and it is not known whether the drug passes into breast milk; the Acetadote label suggests pumping and discarding milk for 30 hours after a dose, while inhaled drug is minimally absorbed. If side effects are severe or persist, talk to your prescriber or pharmacist.
Mucolytic activity derives from the free sulfhydryl group, which cleaves disulfide linkages in mucoproteins; hepatoprotection derives from maintaining or restoring glutathione and binding the toxic acetaminophen metabolite, with reported free radical scavenging. After intravenous dosing the terminal half-life is 5.6 hours, protein binding 66 to 87 percent and steady-state volume of distribution 0.47 L/kg. Labeled indications: Acetadote injection for acetaminophen overdose; acetylcysteine inhalation solution for viscid mucus in acute and chronic bronchopulmonary disease, cystic fibrosis, tracheostomy care and diagnostic bronchial studies, and orally for acetaminophen overdose. Prescribers have ordered compounded acetylcysteine ophthalmic drops for keratoconjunctivitis sicca, and the literature describes off-label use in acute hepatic failure, contrast nephropathy prevention and psychiatric conditions, with evidence graded as limited (StatPearls, 2024). Dosing and route per prescriber. Monitoring: anaphylactoid reactions during IV administration (rate related, more frequent in reactive airway disease), bronchospasm with inhalation, hepatic panel and INR in overdose (IV acetylcysteine can falsely raise INR and urine ketones), and fluid status in heart failure. The inhalation label lists tetracyclines, erythromycin lactobionate, ampicillin, several enzymes and hydrogen peroxide as incompatible in nebulizer admixtures.
Wash your hands. Open one capsule and empty the powder into the volume of saline or water on your label, using only distilled, sterile, or boiled and cooled water if you are mixing it yourself. Stir or shake until dissolved. For a sinus rinse, lean over a sink and rinse each nostril with the device. For a nebulizer, pour the solution into the medicine cup and breathe normally through the mouthpiece or mask until the mist stops. Wash and air dry the rinse device or nebulizer cup after each use. Discard any mixed solution you do not use.
Keep the unopened capsules tightly closed in a dry place at room temperature and out of reach of children. The beyond-use date on your label depends on how the capsules were prepared and what they are for; the pharmacist sets it. Mix only one dose at a time and discard capsules after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Empty contents of 1 capsule and mix with saline solution and irrigate/nebulize
